

cofc



PATENT
ATTORNEY DOCKET NO. 00742/056003

Certificate of Mailing: Date of Deposit: 1/11/06

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Attention: Certificate of Correction Branch.

Antonio J. Freitas
Printed name of person mailing correspondence

Antonio J. Freitas
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Junying Yuan et al.	Art Unit:	1626
Serial No.:	09/688,015	Examiner:	A. Small
Filed:	October 13, 2000	Customer No.:	21559
Patent No.:	6,756,394 B1		
Issued:	June 29, 2004		
Title:	SMALL MOLECULE INHIBITORS OF NECROSIS		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Attention: Certificate of Correction Branch

Certificate
JAN 19 2006
of Correction

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322

Applicants hereby requests that a Certificate of Correction be issued in the patent identified above. The error to be corrected is described in detail on the enclosed PTO Form 1050. Applicants note that the references cited on the enclosed PTO Form 1449 were initialed by the Examiner but are not included in the patent identified above.


JAN 19 2006

No fee is believed to be due, as the error to be corrected was made by the PTO. If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Date:

January 11, 2006

Respectfully submitted,



Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

JAN 19 2006

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. 6,756,394 ^{B1}
 DATED June 29, 2004
 INVENTORS Yuan et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the cover sheet, in "References Cited", in "Other Publications", insert --Borner et al., "Apoptosis Without Caspases: An Inefficient Molecular Guillotine?," *Cell Death Differ.* 6:497-507 (1999).
 Búyúkbíngól et al., "Studies on the Synthesis and Structure-Activity Relationships of 5-(3'-Indolal)-2-Thiohydantoin Derivatives as Aldose Reductase Enzyme Inhibitors," *Farmaco* 49:443-447 (1994).
 Chi et al., "Oncogenic Ras Triggers Cell Suicide Through the Activation of a Caspase-Independent Cell Death Program in Human Cancer Cells," *Oncogene* 18:2281-2290 (1999).
 Fiers et al., "More Than One Way to Die: Apoptosis, Necrosis and Reactive Oxygen Damage," *Oncogene* 18:7719-7730 (1999).
 Herceg et al., "Failure of Poly(ADP-Ribose) Polymerase Cleavage by Caspases Leads to Induction of Necrosis and Enhanced Apoptosis," *Mol. Cell. Biol.* 19:5124-5133 (1999).
 Hirsch et al., "The Apoptosis-Necrosis Paradox. Apoptogenic Proteases Activated After Mitochondrial Permeability Transition Determine the Mode of Cell Death," *Oncogene* 15:1573-1581 (1997).
 Holler et al., "Fas Triggers an Alternative, Caspase-8-Independent Cell Death Pathway Using the Kinase RIP as Effector Molecule," *Nature Immunol.* 1:489-495 (2000).
 Kawahara et al., "Caspase-Independent Cell Killing by Fas-Associated Protein with Death Domain," *J. Cell Biol.* 143:1353-1360 (1998).
 Khwaja et al., "Resistance to the Cytotoxic Effects of Tumor Necrosis Factor Alpha can be Overcome by Inhibition of a FADD/Caspase-Dependent Signaling Pathway," *J. Biol. Chem.* 274:36817-36823 (1999).
 Kitanaka et al., "Caspase-Independent Programmed Cell Death with Necrotic Morphology," *Cell Death Differ.* 6:508-515 (1999).
 Leist et al., "Inhibition of Mitochondrial ATP Generation by Nitric Oxide Switches Apoptosis to Necrosis," *Exp. Cell Res.* 249:396-403 (1999). --

(Correction continued on next sheet)

 MAILING ADDRESS OF SENDER:

Kristina Bieker-Brady, Ph.D.
 Clark & Elbing LLP
 101 Federal Street
 Boston, MA 02110
 Customer No.: 21559

PATENT NO. 6,756,394
 NO. ADDITIONAL COPIES
 @ 50¢ PER PAGE

SUBSTITUTE FORM PTO 1050

JAN 19 2006

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. 6,756,394 ^{B1}
 DATED June 29, 2004
 INVENTORS Yuan et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(Continued from previous sheet)

On the cover sheet, in "References Cited", in "Other Publications", insert --Li et al., "Induction of Necrotic-Like Cell Death by Tumor Necrosis Factor Alpha and Caspase Inhibitors: Novel Mechanism for Killing Virus-Infected Cells," *J. Virol.* 74:7470-7477 (2000).
 Lüschen et al., "Sensitization to Death Receptor Cytotoxicity by Inhibition of Fas-Associated Death Domain Protein (FADD)/Caspase Signaling. Requirement of Cell Cycle Progression," *J. Biol. Chem.* 275:24670-24678 (2000).
 Matsumura et al., "Necrotic Death Pathway in Fas Receptor Signaling," *J. Cell Biol.* 151:1247-1255 (2000).
 McCarthy et al., "Inhibition of Ced-3/ICE-Related Proteases does not Prevent Cell Death Induced by Oncogenes, DNA Damage, or the Bcl-2 Homologue Bak," *J. Cell Biol.* 136:215-227 (1997).
 Sané et al., "Caspase Inhibition in Camptothecin-Treated U-937 Cells is Coupled with a Shift from Apoptosis to Transient G₁ Arrest Followed by Necrotic Cell Death," *Cancer Res.* 59:3565-3569 (1999).
 Vercammen et al., "Inhibition of Caspases Increases the Sensitivity of L929 Cells to Necrosis Mediated by Tumor Necrosis Factor," *J. Exp. Med.* 187:1477-1485 (1998).
 Vercammen et al., "Dual Signaling of the Fas Receptor: Initiation of Both Apoptotic and Necrotic Cell Death Pathways," *J. Exp. Med.* 188:919-930 (1998).--

Column 10, Line 36, replace "in co a" with --in a--.

Column 21, Line 53, replace "chemical" with --chemical compound--.

MAILING ADDRESS OF SENDER:
 Kristina Bieker-Brady, Ph.D.
 Clark & Elbing LLP
 101 Federal Street
 Boston, MA 02110
 Customer No.: 21559

PATENT NO. 6,756,394
 NO. ADDITIONAL COPIES
 @ 50¢ PER PAGE

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. 6,756,394 B1
DATED June 29, 2004
INVENTORS Yuan et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 23,

Line 44, replace "methoxyl," with --methoxyl, amino,--; and
Line 47, replace "acyl," with --acyl, halogen,--.

Column 24, Line 36, replace "alyl" with --alkyl--.

MAILING ADDRESS OF SENDER:
Kristina Bieker-Brady, Ph.D.
Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Customer No.: 21559

PATENT NO. 6,756,394
NO. ADDITIONAL COPIES
@ 50¢ PER PAGE

SUBSTITUTE FORM PTO 1050

JAN 19 2006

Sheet 1 of 2

#4
NP
3/19/01

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 00742/056003 Serial No. 09/688,015 Applicant Junying Yuan et al. Filing Date October 13, 2000 Group 1614 IDS Filed March 9, 2001 Customer No. 21559		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)						
(37 CFR §1.98(b))						
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
AMB	Bomer et al., "Apoptosis without caspases: an inefficient molecular guillotine?," <i>Cell Death Differ.</i> 6:497-507 (1999). -					
AMB	Büyükbıngöl et al., "Studies on the synthesis and structure-activity relationships of 5-(3'-indolal)-2-thiohydantoin derivatives as aldose reductase enzyme inhibitors," <i>J. Farmaco</i> 49:443-447 (1994).					
AMB	Chi et al., "Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells," <i>Oncogene</i> 18:2281-2290 (1999).					
AMB	Fiers et al., "More than one way to die: apoptosis, necrosis and reactive oxygen damage," <i>Oncogene</i> 18:7719-7730 (1999).					
AMB	Herceg et al., "Failure of poly(ADP-ribose) polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis," <i>Mol. Cell Biol.</i> 19:5124-5133 (1999).					
AMB	Hirsch et al., "The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death," <i>Oncogene</i> 15:1573-1581 (1997).					
AMB	Holler et al., "Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule," <i>Nature Immunol.</i> 1:489-495 (2000).					
AMB	Kawahara et al., "Caspase-independent cell killing by Fas-associated protein with death domain," <i>J. Cell Biol.</i> 143:1353-1360 (1998).					
AMB	Khwaja et al., "Resistance to the cytotoxic effects of tumor necrosis factor alpha can be overcome by inhibition of a FADD/caspase-dependent signaling pathway," <i>J. Biol. Chem.</i> 274:36817-36823 (1999).					
AMB	Kitanaka et al., "Caspase-independent programmed cell death with necrotic morphology," <i>Cell Death Differ.</i> 6:508-515 (1999).					
EXAMINER			DATE CONSIDERED 5/24/01			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

RECEIVED
 MAR 15 2001
 TECH CENTER 1600/2900

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE		Attorney Docket No. 00742/056003 Serial No. 09/688,015 Applicant Junying Yuan et al. Filing Date October 13, 2000 Group 1614 IDS Filed March 9, 2001 Customer No. 21559
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		
(37 CFR §1.98(b))		



U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

AND	Leist et al., "Inhibition of mitochondrial ATP generation by nitric oxide switches apoptosis to necrosis," <i>Exp. Cell Res.</i> 249:396-403 (1999).
AND	Li et al., "Induction of necrotic-like cell death by tumor necrosis factor alpha and caspase inhibitors: Novel mechanism for killing virus-infected cells," <i>J. Virol.</i> 74:7470-7477 (2000).
AND	Lüschen et al., "Sensitization to death receptor cytotoxicity by inhibition of fas-associated death domain protein (FADD)/caspase signaling. Requirement of cell cycle progression," <i>J. Biol. Chem.</i> 275:24670-24678 (2000).
AND	Matsumura et al., "Necrotic death pathway in Fas receptor signaling," <i>J. Cell Biol.</i> 151:1247-1255 (2000).
AND	McCarthy et al., "Inhibition of Ced-3/ICE-related proteases does not prevent cell death induced by oncogenes, DNA damage, or the Bcl-2 homologue Bak," <i>J. Cell Biol.</i> 136:215-227 (1997).
AND	Sané et al., "Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G ₁ arrest followed by necrotic cell death," <i>Cancer Res.</i> 59:3565-3569 (1999).
AND	Vercammen et al., "Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor," <i>J. Exp. Med.</i> 187:1477-1485 (1998).
AND	Vercammen et al., "Dual signaling of the Fas receptor: Initiation of both apoptotic and necrotic cell death pathways," <i>J. Exp. Med.</i> 188:919-930 (1998).

EXAMINER	DATE CONSIDERED
<i>[Signature]</i>	5/24/01

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

RECEIVED
MAR 15 2001
TECH CENTER 1600/2900